Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, participants must:~* Sign a parental consent form; if appropriate, sign an assent form~* Be between 1 and 17 years of age~* Have proven or probable bacteremia caused by S. aureus based on the traditional culture result, rapid diagnostic test or Gram stain~* If female of childbearing potential, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study~* If male, must take appropriate measures to not get partner pregnant~* Able to comply with the protocol requirements~Exclusion Criteria:~Participants will not be allowed into the study if they:~* Have received a certain amount of antibacterial therapy specific for current bacteremia unless it is demonstrated that the organism is resistant to the given antibacterial;~* Anticipate to require other antibiotics that may be potentially effective against S. aureus;~* Have shock or hypotension unresponsive to standard therapy;~* Have received an investigational product or have participated in an experimental procedure within 30 days;~* Have an intolerance or hypersensitivity to daptomycin;~* Have renal insufficiency;~* Have prior history or current evidence of muscle damage (rhabdomyolysis; significant CPK elevation);~* Have history of clinically significant muscular disease, nervous system or seizure disorder, including unexplained muscular weakness, history of peripheral neuropathy, Guillain-Barré or spinal cord injury;~* Have S. aureus pneumonia, empyema, meningitis, or endocarditis

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin - 12 to 17 year olds (Type: EXPERIMENTAL): Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
- Comparator - 12 to 17 year olds (Type: ACTIVE_COMPARATOR): Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
- Daptomycin - 7 to 11 year olds (Type: EXPERIMENTAL): Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
- Daptomycin - 1 to 6 year olds (Type: EXPERIMENTAL): Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
- Comparator - 7 to 11 year olds (Type: ACTIVE_COMPARATOR): Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
- Comparator - 1 to 6 year olds (Type: ACTIVE_COMPARATOR): Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).